Business
Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to trade on the public markets this year.
FEATURED STORIES
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to grow its drug manufacturing sector.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Polarean Imaging plc announces that Jonathan Allis, Non-Executive Director, has assumed the role of Chairman with immediate effect.
Microbix Biosystems Inc., a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, announces that it has completed a non-brokered private placement financing with gross proceeds of $2,355,000, by issuing an aggregate of 11,775,000 units at a price of $0.20 per Unit.
Corteva, Inc. reported financial results for the quarter ended December 31, 2019 and the full year 2019.
The space will offer 1.6 million square feet of collaborative lab, office and lifestyle space.
In honor of Black History Month, BioSpace chose to highlight 10 African American leaders in the life sciences, individuals who have prominent roles in the life sciences and biopharmaceutical industry.
Forbion, a leading European life sciences venture capital firm, announces that Dr. John Montana has joined Forbion as Operating Partner, effective 1st January 2020.
Arbor Biosciences announced a partnership with Biosearch Technologies, the complete genomics portfolio of LGC Group.
Pharma and biotech companies strengthen their leadership teams and boards with this week’s Movers & Shakers.
The newly-released BIO report analyzed data from a survey of nearly 100 BIO member companies that was conducted online from May to June 2019.
The study notes that about half of recent drug approvals were built on a single pivotal clinical trial. Typically, two pivotal, Phase III trials were the norm.